VanEck Vectors Biotech ETF News

The VanEck Biotech ETF (BBH) was launched on 12/20/2011, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of the equity market.

Jared Ablass, Vice President, Portfolio Research at TD Asset Management, speaks with Greg Bonnell about how the biotech sector could benefit once rates start to come down. Why beaten down Biotech stoc

Look into how Biotech ETFs performed after Q4 earnings.

Designed to provide broad exposure to the Healthcare - Biotech segment of the equity market, the VanEck Biotech ETF (BBH) is a passively managed exchange traded fund launched on 12/20/2011.

The biotech space staged a strong comeback at the start of 2024, driven by multi-billion dollar deals, upbeat clinical results and cutting-edge medical advances like CRISPR gene-editing hitting prime-

Generative artificial intelligence was a point of emphasis for investors in 2023. That movement is just getting started.

Biotech sector has potential for outperformance in the next year. VanEck Biotech ETF is a good product to consider for exposure to the sector. BBH focuses on large-cap biotech stocks, offering a more

The VanEck Biotech ETF (BBH) was launched on 12/20/2011, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of the equity market.

VanEck Biotech ETF has outperformed alternative industry ETFs in recent years through its concentration in large-cap leaders. Biotech companies are benefiting from new artificial intelligence tools se

Bank of America expects the Gilead Sciences to jump about 30%, as quoted on CNBC.

In what feels like an eternity in biotechnology terms, broader baskets of the industry's stocks haven't outperformed the S&P 500 Health Care Index annually since 2020. That streak could end this year,

Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the VanEck Biotech ETF (BBH), a passively managed exchange traded fund launched on 12/20/2011.

Look if it's the right time to invest in biotech ETFs to help diversify your portfolio.

The FDA advised to Pfizer, Moderna and Novavax to manufacture single-strain jabs targeting the omicron subvariant XBB.1.5 should prove to be a victory for some biotech ETFs.

Launched on 12/20/2011, the VanEck Biotech ETF (BBH) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the equity market.